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Abstract
Background: Adult height is associated with risk of several diseases, but the breadth of such associations and
whether these associations are primary or due to confounding are unclear. We examined the association of adult
height with 50 diseases spanning multiple body systems using both epidemiological and genetic approaches, the
latter to identify un-confounded associations and possible underlying mechanisms.
Methods: We examined the associations for adult height (using logistic regression adjusted for potential confounders)
and genetically determined height (using a two-sample Mendelian randomisation approach with height-associated
genetic variants as instrumental variables) in 417,434 individuals of white ethnic background participating in the UK
Biobank. We undertook pathway analysis of height-associated genes to identify biological processes that could link
height and specific diseases.
Results: Height was associated with 32 diseases and genetically determined height associated with 12 diseases. Of
these, 11 diseases showed a concordant association in both analyses, with taller height associated with reduced risks
of coronary artery disease (odds ratio per standard deviation (SD) increase in height ORepi = 0.80, 95% CI 0.78–0.81;
OR per SD increase in genetically determined height ORgen = 0.86, 95% CI 0.82–0.90), hypertension (ORepi = 0.83, 95%
CI 0.82–0.84; ORgen = 0.88, 95% CI 0.85–0.91), gastro-oesophageal reflux disease (ORepi = 0.85, 95% CI 0.84–0.86; ORgen =
0.94, 95% CI 0.92–0.97), diaphragmatic hernia (ORepi = 0.81, 95% CI 0.79–0.82; ORgen = 0.91, 95% CI 0.88–0.94), but
increased risks of atrial fibrillation (ORepi = 1.42, 95% CI 1.38–1.45; ORgen = 1.33, 95% CI 1.26–1.40), venous thromboembolism
(ORepi = 1.18, 95% CI 1.16–1.21; ORgen = 1.15, 95% CI 1.11–1.19), intervertebral disc disorder (ORepi = 1.15, 95% CI 1.13–1.18;
ORgen = 1.14, 95% CI 1.09–1.20), hip fracture (ORepi = 1.19, 95% CI 1.12–1.26; ORgen = 1.27, 95% CI 1.17–1.39), vasculitis (ORepi
= 1.15, 95% CI 1.11–1.19; ORgen = 1.20, 95% CI 1.14–1.28), cancer overall (ORepi = 1.09, 95% CI 1.08–1.11; ORgen = 1.06, 95%
CI 1.04–1.08) and breast cancer (ORepi = 1.08, 95% CI 1.06–1.10; ORgen = 1.07, 95% CI 1.03–1.11). Pathway analysis showed
multiple height-associated pathways associating with individual diseases.
Conclusions: Adult height is associated with risk of a range of diseases. We confirmed previously reported
height associations for coronary artery disease, atrial fibrillation, venous thromboembolism, intervertebral disc
disorder, hip fracture and cancer and identified potential novel associations for gastro-oesophageal reflux
disease, diaphragmatic hernia and vasculitis. Multiple biological mechanisms affecting height may affect the
risks of these diseases.
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Background
Epidemiological studies have associated higher adult
height with lower risk of mortality from coronary artery
disease (CAD) and respiratory diseases [1–7] and in-
creased risk of atrial fibrillation (AF) [8, 9], venous
thromboembolism (VTE) [9–11], cancer and cancer in
specific sites [1, 7, 12–16]. Although such studies have
typically adjusted for age, sex and some socio-economic
and behavioral risk factors, the observed associations
may still be due to unmeasured confounding. Height it-
self is determined by genetics and early-life factors, such
as nutrient availability, socio-economic circumstances
and diseases [17–19], and some of these can themselves
impact on risk of some diseases in later life. Precise rea-
son(s) for the association of adult height with risk of
these diseases are not known. In particular, it is unclear
whether the associations are primary (due to shared bio-
logical pathways affecting both adult height and risk of
diseases) and not due to confounding.
Genetic approaches (Mendelian randomisation) that
use genetic variants as instrumental variables have been
used to test for causal relationships between exposure
and disease outcomes [20]. Genotypes are generated at
conception with alleles randomly passed on from each
parent and are independent of environmental and life
style factors that can confound epidemiological analysis.
Also, they cannot be altered by disease and therefore re-
move the possibility of reverse causality. Several recent
studies have used a Mendelian randomisation approach
to assess the relationship of height with selected dis-
eases, including CAD [21, 22], stroke [22], VTE [23] and
cancers [16, 24–28].
A recent genome-wide association studies (GWAS)
meta-analysis involving 253,288 individuals of European
ancestry by the GIANT consortium identified 697
height-associated variants which explain ~ 20% of the
heritability of adult height [29]. Here, using this set of
genetic variants and the breadth and scale of the UK
Biobank [30], we comprehensively evaluated the associa-
tions of adult height with 50 diseases in multiple body
systems in the same population using both traditional
epidemiological and genetic approaches. We additionally
undertook pathway analysis of the height-associated
genes to explore potential biological processes under-
lying the associations.
Methods
Study design and setting
Details of the design of the UK Biobank have been re-
ported elsewhere [30]. Briefly, the UK Biobank is a
population-based longitudinal study that recruited ~
500,000 participants aged 40–69 years during 2006–
2010 from throughout the United Kingdom (UK). Partic-
ipants were recruited by inviting just over 9 million
individuals from central NHS registration databases in
the appropriate age group and living within around 20–
25 miles of 22 recruitment centres established in Eng-
land, Scotland and Wales with an eventual participation
rate of around 5%. Detailed data on sociodemographic,
health status, family history and life style were collected
via questionnaires. Standing height was measured by the
Seca 202 device, and other physical measurements such
as weight and blood pressure were measured at the as-
sessment centres and biological samples were taken for
further analysis.
The UK Biobank data have been linked to Hospital Epi-
sode Statistics (HES), as well as national death registries
and cancer registries. HES data covers admissions to NHS
hospitals in the UK between April 1997 and March 2015,
with the Scottish data dating back as early as 1981. HES
uses International Classification of Diseases ICD 9 and 10
to record diagnosis information, and OPCS-4 (Office of
Population, Censuses and Surveys: Classification of Inter-
ventions and Procedures, version 4) to code operative pro-
cedures. Death registries include all deaths in the UK up
to mid-2015, with both primary and contributory causes
of death coded in ICD-10. Cancer registries cover registra-
tions across the UK from 1970s to 2014 with diagnoses
(coded in ICD9 and 10) acquired from a variety of sources
including NHS and private hospitals, cancer screening
programmes, cancer centres, hospices and nursing homes,
general practices as well as HES, death certificates and
Cancer Waiting Time (CWT) data.
The UK Biobank performed genome-wide genotyping
using the Affymetrix UK BiLEVE Axiom array on first
50,000 participants as part of the BiLEVE study [31] and
subsequently using the Affymetrix UK Biobank Axiom®
array for the remaining cohort. The two arrays are very
similar with over 95% overlap content. Details on geno-
typing, quality control and imputation methodology have
been described elsewhere [32]. The assayed genotype
data from both stages have been jointly imputed provid-
ing genome-wide genotypes on over 70 million SNPs for
each subject.
Study participants
We included 459,324 UK Biobank participants with
genotype data who self-reported as having a white ethnic
background. We excluded 985 participants with missing
height and 22 participants whose height was > 4 stand-
ard deviation (SD) away from the mean (< 131.6 and >
205.6 cm). On the basis of the genetic data, we further
excluded subjects because of uncertain gender (n = 354),
genotype data quality (high missingness, QC failure, etc.)
(n = 7025) and relatedness (kinship coefficient > 0.088)
(n = 33,504). Altogether, we investigated 417,434 unre-
lated individuals of white ethnic background with valid
height measures and genotype data.
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Disease definition
We examined 50 diseases covering six broad categories:
(i) Cardiovascular diseases—coronary artery disease
(CAD), hypertension, peripheral vascular disease
(PVD), heart failure (HF), atrial fibrillation (AF),
venous thromboembolism (VTE), aortic valve
stenosis (AS) and stroke
(ii) Musculoskeletal diseases—osteoarthritis,
osteoporosis, gout, sciatica, and intervertebral disc
disorder (IDD), and hip fracture
(iii)digestive diseases—liver cirrhosis, peptic ulcer,
gastro-oesophageal reflux disease (GORD), irritable
bowel syndrome (IBS), inflammatory bowel disease
(IBD), gallstone, appendicitis, diaphragmatic hernia
and inguinal hernia
(iv) Psychiatric and neurological diseases—anxiety
disorder, depression, bipolar disorder, multiple
sclerosis (MS), epilepsy, dementia and Parkinson’s
disease
(v) Other non-neoplastic diseases—chronic obstructive
pulmonary disease (COPD), asthma, diabetes,
hyperthyroidism, hypothyroidism, glaucoma,
cataract and vasculitis
(vi)Cancer including cancer overall and 11 specific
sites—lung, colorectum, prostate, female breast,
uterus, ovary, kidney, bladder, melanoma, non-
Hodgkin lymphoma and leukemia
We defined cases using both self-reported and registry
data and included both prevalent and incident cases. Case
definition and the proportion of cases that were
self-reported are shown in Additional file 1: Table S1. All
diseases have a minimum of 1000 cases from 417,434 sub-
jects in this study, providing 80% power to detect a relative
15% difference in disease risk (i.e. an odds ratio of at least
1.15 or 0.85) per one SD change in height at α = 0.001.
Statistical analysis
Epidemiological analysis
We used logistic regression to estimate the association
of height with risk of diseases, adjusted for age, sex,
obesity (BMI ≥ 30 kg/m2), socio-economic status (based
on quintiles of Townsend Deprivation Index [33] (an
area-based measure of material deprivation calculated
from census household data with a higher index indicat-
ing more deprived), smoking status (ever smoker, ex-
posed to environmental tobacco smoke, none), physical
activity and for individual diseases, other relevant fac-
tors, which included, where appropriate, waist-hip-ratio
(WHR), systolic blood pressure (SBP), use of insulin,
presence of hay fever/eczema and family history of rele-
vant diseases, and for female diseases, parity, nullipar-
ous, ever use of contraceptive pills and ever on hormone
replacement therapy. Further details of the adjustments
are given in the legend to Fig. 1.
Genetic analysis
We used a two-sample Mendelian randomisation (MR) ap-
proach to assess the association of genetically determined
height with various diseases. Summary statistics for effect
size of the height-associated SNPs were extracted from
Wood et al. [29]. Of the 697 height-associated SNPs, 8 were
unavailable in the genotype data imputed from the Haplo-
type Reference Consortium panel. Of the 691 variants serv-
ing as instrumental variables, 146 were genotyped and 545
were imputed with excellent imputation quality (mean 0.99
and the lowest 0.84). Effects of these height-associated
SNPs on the risk of diseases were estimated with the UK
Biobank data under an additive model adjusting for age,
sex, array type (BiLEVE or main study) and five principal
components. We calculated the ratio estimate for each
height-associated variant [20] and then combined the esti-
mates across all variants using meta-analysis [34]. For each
height-associated variant, we extracted β1 (the effect size of
the association between the variant and height) from pub-
lished table [29], estimated β2 (the effect size of the associ-
ation between the variant and the disease) under an
additive mode of inheritance and computed β3 (the putative
association between height and risk of disease mediated
through that variant) using the equation
β3 ¼ β2β1 and its standard error s3 ¼
ﬃﬃﬃﬃﬃﬃﬃ
1
β21s
−2
2
q
, where s2 is
the standard error of β2.
Estimates of β3 across all the height-associated SNPs were
then pooled using inverse-variance-weighted fixed-effect
meta-analysis to obtain the overall association of genetically
determined height on the risk of the disease [34]. In cases
of high heterogeneity (I2 > 40%), we conducted a
random-effects meta-analysis. The estimated β3 reflect the
logarithm of the odds ratio of developing the disease per
one SD increase in genetically determined height. We ad-
justed the p values for testing 50 diseases using Bonferroni
correction in both epidemiological and genetic analyses.
Sensitivity analysis
The MR analysis assumes a linear relationship between
height and risk of diseases. It relies on certain assump-
tions on the selected SNPs as instruments [20]: they are
(1) associated with height, (2) not associated with con-
founding factors and (3) associated with the diseases
only through their effect on height. We assessed the po-
tential impact of violation of these assumptions using
MR-Egger regression [35] and median-based methods
[36] as sensitivity analysis. Standard MR analysis is
equivalent to performing a weighted regression of the ef-
fect sizes of variant-disease associations (β2) against the
effect sizes of variant-height associations (β1) with no
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intercept term, but MR-Egger conducts such regression
with an unconstrained intercept. The estimated intercept
in the MR-Egger regression [35] can be interpreted as an
estimate of the average pleiotropic effects across the
genetic variants. A non-zero intercept is indicative of
directional pleiotropy, that is, the pleiotropic effects do
not cancel out resulting in a biased MR estimate. We
also conducted three median-based methods [36]: (1)
simple median method which takes the median β3 esti-
mate assuming all variants carry equal weight, (2)
weighted median method which gives more weight to
variants with more precise estimates and (3) penalised
weighted median method which down-weights the con-
tribution of heterogeneous variants. MR-Egger regres-
sion can give consistent estimates even when 100% of
variants are invalid but requires the variants to satisfy a
weaker assumption (the InSIDE assumption), whilst the
weighted median methods can give consistent estimates
as long as at least 50% of the weight comes from variants
without pleiotropic effects. Additionally, we examined
the association of genetically determined height with risk
factors and repeated the genetic analysis excluding SNPs
that showed a nominal association (p < 0.05) with sug-
gested confounding factors. We restricted these sensitivity
analyses to diseases showing evidence of association in
primary genetic analysis (Bonferroni adjusted p < 0.05).
In this study, we defined cases using both self-reported
and registry (hospital episodes, cancer and death regis-
tries) information. To assess any impact of including
self-reported data, we repeated the epidemiological and
genetic analyses defining cases based on registry data
only. Furthermore, we defined cases including both
prevalent and incident cases and have assumed that
there were little changes in exposure of risk factors over
time in the epidemiological analysis. To assess any
impact of this assumption, we repeated the epidemio-
logical analysis defining cases based on incidence only.
Genetic score for height
We calculated a genetic score for height to evaluate the ef-
fect of inheriting number of height-increasing alleles on risk
of diseases. For each variant, we computed a score based
on the posterior probabilities for the height-increasing al-
lele, which is then multiplied by the effect size for height es-
timated by Wood et al. [29]. The genetic score is the sum
of these weighted values across all 691 height-associated
variants. We used regression analysis to assess the propor-
tion of variance of height that can be explained by the gen-
etic score. We divided the study subjects into quartiles
based on their genetic scores with quartile 1 (Q1) carrying
the least number of height-increasing alleles and Q4 carry-
ing the most number of height-increasing alleles. We then
used the Cochran-Armitage trend test to assess the pres-
ence of diseases across quartiles, and logistic regression to
estimate the ORs for the quartiles.
Pathway analysis
To identify possible shared biologic processes between
height and diseases, we identified pathways represented by
the 691 height-associated SNPs using the Ingenuity Path-
way Analysis Software (analysis performed on September
19, 2017). This analysis requires the assignment of each
height-associated SNP to a specific gene. We selected the
genes identified by Wood et al. [29] through their exten-
sive bioinformatics analysis of each locus. From the path-
ways identified, we selected those that contained at least
five genes from among the height-related genes and tested
the association of height and risk of diseases through the
specific pathway by combining disease-specific β3 esti-
mates for all height variants in the pathway using
(See figure on previous page.)
Fig. 1 Epidemiological and genetic associations of height with diseases. Legend: Odds ratio (OR) and 95% confidence intervals per one standard
deviation (SD) increase in height based on observed (epidemiology model) and genetically determined height (genetic model) are shown for a
cardiovascular diseases (coronary artery disease (CAD), peripheral vascular disease (PVD), stroke, hypertension, aortic valve stenosis (AS), heart
failure (HF), venous thromboembolism (VTE) and atrial fibrillation (AF)), b musculoskeletal diseases (osteoporosis, osteoarthritis, gout, sciatica,
intervertebral disc disorder (IDD) and hip fracture), c digestive disorders (liver cirrhosis, peptic ulcer, diaphragmatic hernia, inguinal hernia, gastro-oesophageal
reflux disease (GORD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gallstones and appendicitis), d psychiatric and neurological disorders
(dementia, epilepsy, anxiety disorder, depression, bipolar disorder, Parkinson’s disease and multiple sclerosis (MS)), e other non-neoplastic diseases (chronic
obstructive pulmonary disease (COPD), asthma, diabetes, glaucoma, cataract, hypothyroidism and hyperthyroidism and vasculitis), and f cancers and various
sites. One SD is 9.2 cm; for men and women specific diseases, 1-SD corresponds to 6.8 cm and 6.2 cm, respectively. All epidemiological models were
adjusted for age, sex, obesity (BMI ≥ 30), socio-economic status (Townsend deprivation index in highest quintile), Smoking status (ever smoker, exposed to
environmental tobacco smoke, none), physical activity (vigorous exercise at least once a week or more) and other relevant disease-specific risk factors as
described below: models for CAD—waist-hip-ratio, systolic blood pressure, use of insulin and family history of heart diseases; models for AF, VTE, PVD and
heart failure—systolic blood pressure, use of insulin and family history of heart diseases; model for hypertension—use of insulin and family history of
hypertension; model for stroke—waist-hip-ratio, systolic blood pressure, use of insulin and family history of stroke; model for COPD—family history of COPD;
model for asthma—presence of hay fever or eczema; model for dementia—family history of dementia; depression—family history of depression; Parkinson’s
disease—family history of Parkinson’s disease; model of glaucoma—systolic blood pressure and use of insulin; model for diabetes—waist-hip-ratio, systolic
blood pressure and family history of diabetes; model of cataract—use of insulin; model for cancer overall—family history of lung/breast/prostate/bowel
cancer; model for cancer of the breast—nulliparous, ever use of contraceptive pills, ever on hormone replacement therapy and family history of breast cancer;
models for lung, prostate and colorectal cancers—family history of respective cancers. *p<0.05, **p<0.01, ***p<0.001 after Bonferroni correction for 50 tests
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meta-analysis. The results were not adjusted for multiple
testing as this analysis was exploratory.
Results
Of the 417,434 people included in the study, 54.0% were
women, the mean age at recruitment was 56.8 years
(range 38–73), and the mean height was 168.7 cm (SD
9.2). Taller people were younger, more likely to have a
lower BMI, a lower WHR, and lower blood pressure
(Table 1). They were also less likely to have ever smoked
or be socio-economically deprived and more likely to be
physically active. Taller women were more likely to be
nulliparous and to have ever used the oral contraceptive
pill and less likely to have ever been on hormone re-
placement therapy. Given that taller women were youn-
ger, this observation is likely to be confounded by age.
As expected, people carrying more height-increasing
alleles are taller (Table 2). Regression analyses showed
that the weighted genetic score explained 16.7 and
16.5% of variation of height for women and men, re-
spectively. Individuals in the upper quartiles were mar-
ginally older, with similar sex composition across
quartiles, and appeared to be associated with a slightly
lower BMI, lower blood pressure and lower Townsend
Deprivation Index, but not with smoking history, or
undertaking vigorous physical activity. Women with
higher genetic score are more likely to be nulliparous
and ever on hormone replacement therapy.
Association of height with diseases based on
epidemiological and genetic analyses
The estimated odds ratio (OR) per one SD (9.2 cm) in-
crease in height (epidemiological analysis) and genetically
determined height (genetic analysis) are shown in Fig. 1.
For men and women specific diseases, 1-SD of height cor-
responds to 6.8 and 6.2 cm respectively. Overall, 39 and
23 diseases showed evidence suggestive of epidemiological
and genetic associations with height (p < 0.05), respect-
ively. The height association remained for 32 and 12 dis-
eases (11 in common) after adjusting for multiple testing.
Among cardiovascular diseases, we found inverse epi-
demiological associations of height with CAD, PVD,
stroke, hypertension, AS and HF with an estimated OR
between 0.77 (PVD) and 0.92 (HF) (Fig. 1a). With gen-
etic analyses, we found strong evidence for inverse asso-
ciation for CAD (OR = 0.86, 95% CI 0.82–0.90, p <
0.0001) and hypertension (OR = 0.88, 95% CI 0.85–0.91,
p < 0.0001). In contrast to these inverse associations, tal-
ler height was associated with increased risk of VTE and
AF in both epidemiological (VTE: OR = 1.18, 95% CI
Table 1 Baseline characteristics of participants in the UK Biobank by quartiles of adult height
Characteristic Height (cm) Overall
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Height (cm)—female 132–< 158 158–< 163 163–< 167 167–199 132–199
Height (cm)—male 132–< 171 171–< 176 176–< 180 180–205 132–205
N 87,358 117,771 97,416 114,889 417,434
Age 58.8 (7.5) 57.5 (7.8) 56.4 (7.9) 54.9 (8.1) 56.8 (8.0)
Sex—female 52.8% 55.7% 55.7% 51.6% 54.0%
Body mass index (BMI) 28.1 (4.9) 27.6 (4.8) 27.2 (4.7) 26.8 (4.6) 27.4 (4.8)
Obese (BMI ≥ 30) 28.9% 25.4% 23.0% 20.4% 24.2%
Waist-hip-ratio (WHR) 0.88 (0.1) 0.87 (0.1) 0.87 (0.1) 0.87 (0.1) 0.87 (0.1)
Townsend deprivation indexa 22.5% 18.1% 16.7% 16.1% 18.1%
Ever smoker 47.1% 46.2% 45.5% 45.5% 46.0%
Vigorous activityb 55.5% 58.8% 60.6% 63.0% 59.7%
Systolic BP (mmHg) 145.3 (21.3) 142.3 (20.8) 140.1 (20.5) 137.8 (19.5) 141.2 (20.7)
Diastolic BP (mmHg) 85.4 (11.3) 84.6 (11.3) 84.0 (11.3) 83.4 (11.2) 84.3 (11.3)
Female only
Nulliparous 15.9% 17.3% 19.0% 22.7% 18.8%
Ever oral contraceptive 78.1% 81.3% 83.3% 84.9% 82.0%
Ever on hormone replacement therapy 45.0% 41.6% 38.1% 33.4% 39.3%
Data expressed as mean (SD) for continuous variables or as percentages for categorical variables; missing data—BMI (n = 464), WHR (n = 162), systolic BP (n = 348),
diastolic BP (n = 346), Townsend deprivation index (n = 489), smoking status (n = 1481), physical activity (n = 547), nulliparous (n = 143), oral contraceptive (n = 34)
and hormone replacement therapy (n = 87)
BP blood pressure
aTownsend deprivation index—highest quantile
bVigorous activity—at least once a week for 10+min
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1.16–1.21, p < 0.0001; AF: OR = 1.42, 95% CI 1.38–1.45,
p < 0.0001) and genetic analyses (VTE: OR = 1.15, 95%
CI 1.11–1.19, p < 0.0001; AF: OR = 1.33, 95% CI 1.26–
1.40, p < 0.0001).
Among musculoskeletal diseases, taller stature was
strongly associated with an increased risk of IDD (epi-
demiological OR = 1.15, 95% CI 1.13–1.18, p < 0.0001;
genetic OR = 1.14, 95% CI 1.09–1.20, p < 0.0001) and hip
fracture (epidemiological OR = 1.19, 95% CI 1.12–1.26, p
< 0.0001; genetic OR = 1.27, 95% CI 1.17–1.39, p < 0.0001)
(Fig. 1b). The observed inverse associations of height with
osteoporosis (OR = 0.76, 95% CI 0.73–0.78, p < 0.0001)
and osteoarthritis (OR = 0.95, 95% CI 0.94–0.96, p <
0.0001) in epidemiological analyses were attenuated in
genetic analyses (osteoporosis: OR = 0.96, 95% CI 0.92–
1.00; osteoarthritis: OR = 1.00, 95% CI 0.97–1.03).
Among digestive diseases (Fig. 1c), we found inverse epi-
demiological associations between height and risks of liver
cirrhosis, peptic ulcer, diaphragmatic hernia, GORD, IBS
and IBD, with an estimated OR ranging from 0.76 to 0.91.
For genetic analyses, the inverse height association was ob-
served for diaphragmatic hernia (OR = 0.91, 95% CI 0.88–
0.94, p < 0.0001) and GORD (OR= 0.94, 95% CI 0.92–0.97,
p = 0.0001) only. We also observed epidemiological associ-
ation of height with appendicitis (OR = 1.10, 95% CI 1.06–
1.14, p < 0.0001), but the association was attenuated in gen-
etic analysis (OR = 1.04, 95% CI 0.99–1.09).
Among psychiatric/ neurological diseases, we observed
inverse epidemiological association for dementia, epi-
lepsy, anxiety and depression; however, the correspond-
ing genetic associations were much weakened (Fig. 1d).
Similarly, the inverse associations observed for COPD,
asthma and diabetes in epidemiological analysis were
not found in genetic analysis (Fig. 1e). However, we ob-
served taller height being associated with increased risks
of vasculitis in both epidemiological (OR = 1.15, 95% CI
1.11–1.19, p < 0.0001) and genetic analyses (OR = 1.20,
95% CI 1.14–1.28, p < 0.0001).
Both epidemiological (OR = 1.09, 95% CI 1.08–1.11, p <
0.0001) and genetic analysis (OR = 1.06, 95% CI 1.04–1.08,
p < 0.0001) showed evidence of a positive association of
height with overall cancer (Fig. 1f). Of the 11 sites, height
was associated with 8 and 5 sites at p < 0.05 (unadjusted)
in epidemiological and genetic analyses, respectively. After
adjusting for multiple testing, epidemiological association
remained for four sites: female breast (OR = 1.08, 95% CI
1.06–1.10, p < 0.0001), kidney (OR = 1.17, 95% CI 1.08–
1.27, p = 0.0053), non-Hodgkin lymphoma (OR = 1.19,
95% CI 1.12–1.27, p < 0.0001) and melanoma (OR = 1.21,
95% CI 1.16–1.26, p < 0.0001), and genetic association
Table 2 Characteristics of participants in the UK Biobank by quartiles of weighted genetic score for height
Characteristic Weighted genetic score for heighta
Quartile 1 Quartile 2 Quartile 3 Quartile 4
N 90,170 107,870 109,390 110,004
Height (cm)—female 159.2 (5.7) 161.6 (5.6) 163.3 (5.7) 165.8 (6.0)
Height (cm)—male 172.1 (6.2) 174.7 (6.2) 176.6 (6.2) 179.3 (6.5)
Age 56.7 (8.0) 56.8 (8.0) 56.8 (8.0) 56.9 (7.9)
Sex—female 53.9% 54.0% 53.8% 54.2%
Body mass index (BMI) 27.6 (4.9) 27.5 (4.8) 27.3 (4.7) 27.2 (4.7)
Obese (BMI ≥ 30) 25.5% 24.5% 23.8% 23.1%
Waist-hip-ratio (WHR) 0.87 (0.09) 0.87 (0.09) 0.87 (0.09) 0.87 (0.09)
Townsend deprivation indexb 19.5% 18.2% 17.8% 17.4%
Ever smoker 46.2% 46.2% 45.8% 45.9%
Vigorous activityc 59.4% 59.7% 60.1% 59.4%
Systolic BP (mmHg) 141.7 (20.9) 141.4 (20.7) 141.0 (20.6) 140.6 (20.5)
Diastolic BP (mmHg) 84.6 (11.3) 84.4 (11.3) 84.2 (11.2) 84.1 (11.3)
Female only
Nulliparous 18.7% 18.4% 18.7% 19.5%
Ever contraceptive pill 81.9% 82.0% 82.2% 82.0%
Ever on hormone replacement therapy 38.8% 39.2% 39.4% 39.8%
Data expressed as mean (SD) for continuous variables or as percentages for categorical variables; missing data—BMI (n = 464), WHR (n = 162), systolic BP (n = 348),
diastolic BP (n = 346), Townsend deprivation index (n = 489), smoking status (n = 1481), physical activity (n = 547), nulliparous (n = 143), oral contraceptive (n = 34)
and hormone replacement therapy (n = 87)
BP blood pressure
aQuartile 1 of the genetic score carrying the least number and quartile 4 the most number of height-increasing alleles
bTownsend deprivation index—highest quantile
cVigorous activity—at least once a week for 10+min
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remained for two sites: breast (OR = 1.07, 95% CI 1.03–
1.11, p = 0.0366) and colorectum (OR = 1.11, 95% CI
1.05–1.18, p = 0.0307).
Sensitivity analysis
For the 12 diseases showing an association with genetic-
ally determined height, the intercept tests from the
MR-Egger regression revealed little evidence for plei-
otropy (Table 3). The associations revealed by MR-Egger
regression and median-based methods were broadly simi-
lar to the primary genetic analyses for the nine non-neo-
plastic diseases. For cancer overall, the OR estimates from
MR-Egger and weighted median methods remained simi-
lar to the primary genetic analysis. For breast cancer and
colorectal cancer, the sensitivity analysis appears to sug-
gest a weaker or null genetic association.
We found that genetically determined height was associ-
ated with obesity, blood pressure, Townsend Deprivation
Index and nulliparity (Additional file 2: Table S2). We re-
peated the genetic analyses excluding SNPs that were as-
sociated with these factors. This showed little impact on
the estimates of the genetic associations, apart from the
anticipated effect when excluding SBP-associated SNPs,
which weakened the genetic association for hypertension.
(Additional file 2: Table S3).
The estimates for using registry-based cases only were
similar to that for using both self-reported and registry-
based cases (Additional file 2: Table S4). This suggests little
impact on using self-reported data. In addition, we repeated
the epidemiological analysis excluding prevalent cases at
baseline. There were no significant changes in the esti-
mates, except for IDD in which the association appeared to
have become much weakened (Additional file 2: Table S5).
The confidence intervals for the estimates as expected be-
came wider due to reduced statistical power.
Genetic score of height and odds ratios of diseases
For the 12 diseases associated with genetically determined
height, all exhibited a trend (p < 0.05) in either increasing
or decreasing risk with carriage of more height-raising al-
leles (Fig. 2), and the directions were compatible with the
findings from the primary genetic analysis. Compared
with subjects in Q1, those in Q4 had a decreased risk of
CAD (OR = 0.87, 95% CI 0.84–0.91, p < 0.001),
Fig. 2 Risk of disease by quartiles of weighted genetic score for height. Legend: CAD coronary artery disease, VTE venous thromboembolism, AF
atrial fibrillation, IDD intervertebral disc disorder and GORD gastro-oesophageal reflux disease. Associations by quartile of weighted genetic score
for height are shown for the 12 diseases which showed an association with genetically determined height (Bonferroni p value < 0.05). Individuals
in quartile 1 (Q1) (reference quartile) carry the least number, and Q4 carry the highest number of height-increasing alleles. p values for trends
(GORD Ptrend = 0.003, colorectal cancer Ptrend = 0.003 and breast cancer Ptrend = 0.010, all other diseases Ptrend < 0.001
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hypertension (OR = 0.92, 95% CI 0.90–0.94, p < 0.001),
GORD (OR = 0.95, 95% CI 0.92–0.98, p = 0.002) and dia-
phragmatic hernia (OR = 0.90, 95% CI 0.87–0.93, p <
0.001). In contrast, there were increased risks of AF (OR
= 1.43, 95% CI 1.36–1.50, p < 0.001), VTE (OR = 1.16, 95%
CI 1.11–1.21, p < 0.001), IDD (OR = 1.16, 95% CI 1.11–
1.21, p < 0.001), hip fracture (OR = 1.34, 95% CI 1.19–1.51,
p < 0.001), vasculitis (OR = 1.23, 95% CI 1.14–1.33, p <
0.001) and cancer (OR = 1.07, 95% CI 1.05–1.10, p <
0.001) along with two specific sites female breast (OR
= 1.06, 95% CI 1.004–1.11, p = 0.035) and colorectum
(OR = 1.13, 95% CI 1.04–1.22, p = 0.004) for subjects in
Q4 compared with Q1.
Biological pathways
We identified 202 Ingenuity pathways which included
five or more genes from amongst the 691 height-related
variants (Additional file 1: Table S6). Table 4 shows the
top five pathways associated with each disease. There
was little overlap in the pathways showing the strongest
association with individual diseases. Furthermore, no in-
dividual pathway explains the majority of the association
with any disease.
Discussion
Our combined epidemiological and genetic analysis showed
that adult height is associated with risk of many diseases af-
fecting multiple body systems. We observed a concordance
between the epidemiological and genetic analyses for 11
diseases suggesting a primary association between height
and risk of these diseases. For colorectal cancer, the genetic
analyses suggested a strong association with height but the
epidemiological association was slightly weaker. For some
diseases (e.g. HF, COPD), we observed an epidemiological
association but a much weaker or null genetic association
suggesting that the epidemiological associations, despite ad-
justment for potential confounders, likely remain subject to
residual confounding.
We used a large number of genetic variants as instru-
ments in our analysis. It is plausible that some of these vari-
ants have effects on disease development that are not
linked/mediated through their effects on height (pleiotropy).
However, among diseases that showed an association with
genetically determined height, we observed trends between
carrying more height-raising alleles and disease risk (Fig. 2),
evidencing a dose response relationship that supports the
role of height, or shared biological mechanisms related to
both height and the development of disease.
Our analysis does not exclude the possibility that height
itself induces behaviour or reflects circumstances that im-
pact on disease risk. For example, genetically determined
height appeared to be associated with a lower Townsend
Deprivation Index suggesting the potential impact of
genetically determined traits on socio-economic outcomes,
which could subsequently impact on disease (Additional file 2:
Table S2). However, excluding height-related variants that
also associated with Townsend Deprivation Index did not at-
tenuate the observed associations (Additional file 2: Table
S3). In the sensitivity analysis, the weighted penalised median
produced a weakened association compared with the pri-
mary genetic analysis for breast and colorectal cancer, sug-
gesting the possibility of non-homogeneity of the casual
effect across variants. Whilst this may lead to incorrect esti-
mate and affect the interpretation of the results, this may not
lead to inappropriate inferences [37]. For most diseases in
this study, the MR-Egger and weighted median analysis pro-
vided consistent estimates with the standard genetic analysis,
together with the intercept tests of MR-Egger, supporting the
validity of the selected genetic instruments (Table 3).
Turning to individual sets of diseases, the concordant
inverse associations between height and risks of CAD in
both epidemiological and genetic analyses, together with
the absence of any attenuation of the genetic association
from exclusion of lipid-related variants [21], suggests a
primary impact of shorter height on the vasculature that
predisposes to atherosclerotic disease. Our estimate of
OR of 0.86 per 1-SD (9.2 cm) increase in genetically de-
termined height agrees with previous reports [21, 22]
which showed an estimated equivalent OR of 0.83–0.86.
Shorter people have smaller caliber vessels which could
cause symptomatic disease despite similar plaque burden
[38, 39]. Height also affects pulsatile arterial haemo-
dynamics with increased augmentation of central systolic
pressure in shorter people [40] that could influence dis-
ease risk in multiple vascular beds.
Our study found evidence of a possible primary associ-
ation between taller height and risk for AF. Increased
atrial size has been recognised as a risk factor of AF
[41]. Given the association between body size and left
atrial size [42], it is plausible that the height-AF associ-
ation may be mediated through atrial size. Previous epi-
demiological studies have reported a positive association
between height and VTE [9–11], and our study supports
a genetic role of height. One recent study showed an
OR = 1.34 per 10 cm increase in genetically determined
height [23], which appeared to be strong than our esti-
mate of OR = 1.15 per 9.2 cm increase in genetically de-
termined height, but this study used the genetic risk
score (GRS) as the single instrumental variable as op-
posed to using the variants that comprise the GRS as
the instrumental variables in our study and this may lead
to the difference in the effect estimates [35]. Taller
height is associated with an increased risk of VTE. It is
possible that greater venous surface area in taller people
increases the risk of VTE.
Extending previous epidemiological studies [43, 44],
we found a positive relationship between height and risk
of IDD. Whilst the mechanisms remain to be identified,
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one possible mechanism may be through facet tropism
(asymmetry in left and right facet joint angles of lumbar
spine) [45]. In addition, our result agrees with a recent
meta-analysis of prospective cohort studies which con-
cluded a positive association between height and risk of
hip fracture [46]. It is plausible that the association
might be mediated with hip axis length, given that
height is positively associated with hip axis length [47],
which has been reported as a risk factor of hip fracture
[48]. Our study also found evidence for a negative asso-
ciation between height and risks of diaphragmatic hernia
and GORD. Given that hiatal hernia is the most com-
mon type of diaphragmatic hernia, and that it plays an
important role in the pathogenesis of GORD [49], it is
not surprising height has the same directional impact to
the risk of developing these two diseases. Whilst the
mechanisms remain unclear, a prior hypothesis is that
shorter people have greater intra-abdominal pressure,
which increases the risk of developing hiatal hernia and
subsequent reflux symptoms [50]. Our study also found
strong evidence for a positive association between adult
height and vasculitis. This suggests a possible link be-
tween height and some aspects of immune function al-
though this requires further investigation. To our
knowledge, this is the first analysis performed to evalu-
ate the association of height with risks of diaphragmatic
hernia, GORD and vasculitis.
Consistent with previous epidemiological reports [1, 7,
12–15], we found that taller height was associated with a
higher overall risk of cancer. One recent study [27] using
the UK Biobank showed an OR of 1.10 (95% CI 1.07–
1.13) per 1-SD increase in genetically determined height,
which appeared to be slightly stronger than our estimate
(OR = 1.06, 95% CI 1.04–1.08 per 1-SD in genetically de-
termined height), but one should note the difference in
the study designs. Ong et al. [27] excluded self-reported
cancer cases, used 2059 genetic variants as instrumental
variables and conducted the analysis using the
SNP-height and SNP-cancer effects all derived within
the UK Biobank. Overlapping subjects in a two-sample
MR is known to induce bias [51], and our estimate is po-
tentially more accurate. Nonetheless, these studies
strongly suggested that the positive association of height
and cancer is primary (not due to confounding), poten-
tially reflecting multiple shared mechanisms influencing
cellular growth (Table 4). There were concordant trends
towards higher risk with both observed and genetically
determined height for various site-specific cancers
(Fig. 1f ). The diversity of the types of cancers associated
with height and their magnitude of associations sug-
gested that there may be different biological mechanisms
by which height affects the risks. We observed concord-
ant epidemiological and genetic evidence for breast can-
cer. Our genetic estimate of OR = 1.07 per 6.2 cm
increase (equivalent to OR = 1.12 per 10 cm increase) is
similar to previous reports of OR = 1.19 and 1.22 per
10 cm increase in genetically determined height [16, 24].
Our study also agrees with previous studies showing evi-
dence of genetically determined height with risk of colo-
rectal cancer [26], and little evidence with prostate
cancer [16, 25]. It is interesting to note that for lung
cancer, the genetic and epidemiological associations
were in opposite directions, although both associations
were not found statistically significant after adjustment
for multiple testing suggesting that the observed associa-
tions could be due to chance. It is also possible that the
epidemiological finding here for lung cancer remains
subject to confounding. Our genetic estimate of OR =
1.15 per 9.2 cm increase is consistent with previous re-
port of OR = 1.10 per 10 cm increase in genetically de-
termined height [16]. Previous epidemiological report in
women population suggested possible effect modifica-
tion by smoking status for smoking-related cancers [14],
but our epidemiological analysis did not show evidence
of difference in height-lung cancer risks between ever
and never smokers (interaction of height with smoking
status p = 0.723).
Our pathway analysis showed that there were differ-
ent height-associated pathways influencing risks of in-
dividual diseases (Table 4). Several of these pathways
have been linked to diseases or disease risk in their re-
spective categories, although in many cases, the rela-
tionship between the pathways and the disease risks are
not very well understood. Nitric oxide signalling has a
known relationship to CAD risk [52], and Wnt signal-
ling has been linked to AF [53]. We also found a link
between Wnt signalling and IDD, but its role with the
disease remains to be investigated. In addition, we ob-
served a link of glioma signalling with VTE and the role
of tissue factor in cancer. Several studies suggested pos-
sible link of VTE with malignant glioma [54, 55] and
other forms of cancer [56]. In this study, we also noted
an association of Sphingosine-1-phosphate (S1P) signal-
ling with both the ‘cancer overall’ and colorectal cancer
disease categories. S1P is known to have a role in
tumorigenesis and tumor growth [57] and has been
linked with multiple cancer types and has an associ-
ation with intestinal inflammation and tumorigenesis
[58]. The role of Rho GTPases in the development of
colorectal cancer has been reported [59], and this is
consistent with our finding of the link of ‘signalling by
Rho family GTPases’ pathway with colorectal cancer.
Limitations of study
Whilst the scale and breadth of the UK Biobank and the
ability to examine and directly compare both epidemio-
logical and genetic associations in the same population
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are particular strengths of our analysis, some limitations
need to be highlighted. Although large, the UK Biobank
may not be representative of the UK population. There
is a skew towards individuals in higher socio-economic
groups [30]. Despite a low response rate, the fact that
the associations reported in this paper largely agree with
other studies, is reassuring. We included both prevalent
and incident cases in the primary epidemiological ana-
lysis and assumed the exposure of risk factors recorded
at baseline remained constant. Our sensitivity analysis
revealed generally little impact of the current design as
opposed to a prospective design which includes incident
cases only. Our design allowed consistent case definition
for both genetic and epidemiological analyses and en-
abled maximum statistical power for detection of associ-
ation. Finally, there were a small minority of non-White
participants in the UK Biobank. We restricted our ana-
lysis to individuals of a White ethnic background, and it
remains to be shown whether the height-related associa-
tions apply to other ethnic groups.
Conclusion
Adult height is associated with risks of diseases in mul-
tiple body systems. Our study, using both epidemio-
logical and genetic approaches, not only confirmed
previously reported height associations for CAD, AF,
VTE, IDD, hip fracture and cancer, but also identified
potential novel associations for GORD, diaphragmatic
hernia and vasculitis. It suggests complex relationship
between adult height and risk of diseases and shared
biological mechanisms underpinning many of the ob-
served height-disease associations.
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